Risk of colorectal cancer after initiation of orlistat: matched cohort studyBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f5039 (Published 27 August 2013) Cite this as: BMJ 2013;347:f5039
- Jin-Liern Hong, doctoral student1,
- Christoph R Meier, professor234,
- Robert S Sandler, professor15,
- Susan S Jick, director and professor4,
- Til Stürmer, professor1
- 1Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, McGavran-Greenberg, CB # 7435, Chapel Hill, NC 27599-7435, USA
- 2Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
- 3Hospital Pharmacy, University Hospital, Basel, Switzerland
- 4Boston Collaborative Drug Surveillance Program, Boston University School of Public Health, Boston, MA 02421, USA
- 5Department of Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill NC 27599-7555, USA
- Correspondence to: J L Hong
- Accepted 17 July 2013
Objective To examine the risk of colorectal cancer after orlistat initiation in the UK population.
Design Retrospective matched cohort study.
Setting Data from the UK Clinical Practice Research Datalink from September 1998 to December 2008.
Participants 33 625 adults aged 18 years or over who started treatment with orlistat; each orlistat initiator was matched to up to five non-initiators (n=160 347) on age, sex, body mass index, and calendar time.
Main outcome measures Associations between orlistat initiation and the risk of colorectal cancer, assessed by calculating hazard ratios with propensity score adjusted Cox proportional hazard models.
Results Of 193 972 patients with a median age of 47 (interquartile range 37-57) years, 77% were women and approximately 90% were obese (body mass index ≥30). Orlistat initiators were more likely to have a previous history of diabetes or hypertension and to receive prescriptions for anti-diabetes drugs, statins, and aspirin compared with non-initiators. In the intention to treat analysis, 57 colorectal cancer events were identified among orlistat initiators and 246 among non-initiators, with median follow-up times of 2.96 and 2.86 years, respectively. The calculated incidence rate of colorectal cancer per 100 000 person years was 53 (95% confidence interval 41 to 69) for orlistat initiators and 50 (44 to 57) for non-initiators. Orlistat initiation was not associated with a higher risk of colorectal cancer (adjusted hazard ratio 1.11, 95% confidence interval 0.84 to 1.47). Findings were robust in the as treated analyses and in patients who were aged 50 years or over, were morbidly obese, or had a history of diabetes.
Conclusions This study found no evidence of an increased risk of colorectal cancer after the initiation of orlistat. It is limited by the relatively short follow-up time, and the possibility of adverse effects of long term orlistat use on risk of colorectal cancer cannot be excluded.
Orlistat is an anti-obesity drug that reduces the absorption of dietary fat by inhibiting lipase and is currently approved for both prescription (Xenical, Roche) and over the counter (Alli, GlaxoSmithKline) sale in the United States and Europe. Long term treatment with orlistat has been shown to significantly reduce weight and waist circumference and to have beneficial effects on blood pressure, lipids, and type 2 diabetes.1 2 3 4 5
An animal study found that orlistat was associated with a significant increase in the number of colonic aberrant crypt foci, independent of high fat diet.6 This result is supported by another preclinical study, which showed that orlistat induced colonic cell proliferation and severe crypt alternation.7 Aberrant crypt foci are putative precursors of colon cancer, although controversy has arisen about aberrant crypt foci as a biomarker of colorectal cancer.8 9 10 An analysis of pooled clinical trials conducted by orlistat manufactures found no statistically significant difference in risk of colorectal cancer between orlistat and placebo groups.11 Nevertheless, the pooled analysis showed a numerical imbalance in colorectal carcinoma favoring placebo and was not adequately powered to detect a clinically relevant increased risk. Six of 9717 patients taking orlistat developed colon cancer compared with only one of 7912 patients on placebo. Furthermore, randomized trials tend to recruit younger and healthier patients. On the basis of a review of available data and literature, the US Food and Drug Administration concluded that no evidence existed of a causal relation between use of orlistat and the risk of colorectal cancer.12
Orlistat is currently the top selling drug in the global market of anti-obesity drugs, with worldwide sales of $663m (£427m; €496m) in 2011, according to a report from EvaluatePharma.13 Given such extensive use of orlistat, the lack of data from population based studies on its effects on the risk of colorectal cancer is a major concern. In this study, we sought to investigate whether orlistat initiation would affect the risk of colorectal cancer in a large cohort of adults in the United Kingdom.
We did a retrospective matched cohort study using data from the UK Clinical Practice Research Datalink (CPRD) from September 1998 to December 2008. Orlistat was available only by prescription in the UK during our study period.
We considered patients to be new users of orlistat if they were aged 18 years or over, had been actively recorded in the CPRD for at least 12 months before starting orlistat treatment without use of any prescription for anti-obesity drugs (orlistat, sibutramine, rimonabant, phentermine, and diethylpropion), and had a body mass index recorded within 12 months before starting treatment. We further restricted new users of orlistat to those who had a second orlistat prescription on or before the end of drug supply of the first orlistat prescription plus a 15 day grace period. We used the date of the second prescription to define cohort entry (the start date). For each orlistat initiator, we randomly selected up to five non-initiators from patients who had body mass index recorded and did not start any prescription anti-obesity drug on the start date of the corresponding orlistat initiator or in the previous 12 months, further matched on age, sex, and body mass index (within 1 unit). We assigned each non-initiator the same start date of his/her matched orlistat initiator. We excluded patients in both cohorts if they had diagnosis of colorectal adenoma, familial polyposis, or any type of cancer (except non-melanoma skin cancer) before the start date.
Incident colorectal cancer was the outcome in this study. We ascertained diagnosis of colorectal cancer through Read codes during follow-up, including malignant neoplasm and carcinoma in the colon and rectum.
We did both intention to treat and as treated analyses. In the intention to treat analysis (first treatment carried forward), we considered patients to be exposed to the initial treatment (orlistat versus none) until administrative censoring, ignoring any subsequent changes in treatment. In the as treated analysis, we considered orlistat initiators to be exposed until 180 days after the discontinuation of orlistat or an additional prescription for any other anti-obesity drug; we censored non-initiators for initiation of any anti-obesity drug. We chose 180 days to allow for a carry-over effect or latency period of cancer detection. In both analyses, the follow-up started at 180 days after the start date to account for an induction period of cancer pathogenesis in both cohorts and ended with the earliest of death, any type of cancer (except non-melanoma skin cancer), migration out of the healthcare system, or end of the study period.
We used a Cox proportional hazards model with robust variance to estimate the hazard ratios of colorectal cancer, overall and over time, and their corresponding 95% confidence intervals. To control confounding, we first assembled cohorts by matching and then controlled for remaining imbalances by using propensity scores weighting.14 15 We used this two step approach because we intended to control tightly for age, sex, and body mass index, which are the most important confounders in this study, without the need to rely on correct specification of multivariable models.
We did sensitivity analyses to assess the robustness of our assumptions of induction and latency periods. We repeated the main analysis with various lengths of time for induction and latency periods. Note that intention to treat analysis is an extreme form of (infinite) latency. We also did subgroup analyses. We used SAS software (version 9.2) for all statistical analyses.
This study included 33 625 orlistat initiators and 160 347 matched non-initiators. Of all non-initiators, 20 664 started anti-obesity drugs during follow-up. Table 1⇓ compares the characteristics of orlistat initiators and non-initiators. Compared with non-initiators, orlistat initiators had a slightly higher prevalence of diabetes and hypertension at baseline and were more likely to receive drugs, including oral anti-diabetes drugs, statins, and non-steroidal anti-inflammatory drugs. After propensity scores weighting, baseline characteristics were well balanced between orlistat initiators and non-initiators.
Table 2⇓ shows incidence rates and hazard ratios of colorectal cancer. In the intention to treat analysis, we observed 57 colorectal cancers among orlistat initiators and 246 among non-initiators during 106 708 and 488 526 person years of follow-up. The incidence rate of colorectal cancer per 100 000 person years was 53 (95% confidence interval 41 to 69) for orlistat initiators and 50 (44 to 57) for non-initiators. The hazard ratio of colorectal cancer comparing orlistat initiators with non-initiators was 1.11 (95% confidence interval 0.84 to 1.47) after propensity scores weighting. In the as treated analysis, the mean follow-up time and the number of colorectal cancer cases were lower owing to treatment changes, whereas the hazard ratio estimates were similar to the results of the intention to treat analysis. We further examined the effect of orlistat on the risk of colorectal cancer over the follow-up time (fig 1⇓), and we observed no increased risk of colorectal cancer and no clear trend of the hazard ratios over time.
We did sensitivity analyses to evaluate the robustness of the results with respect to the assumptions of induction and latency periods (tables 3⇓ and 4⇓). The absence of an effect of orlistat initiation on the risk for colorectal cancer was consistent through the range of induction and latency periods assessed in both intention to treat and as treated analyses. We also did subgroup analyses. The results showed that orlistat was not associated with an increased risk of colorectal cancer in analyses stratified according to age (≥50 or <50 years), sex, body mass index (≥35 or <35), or the presence or absence of diabetes at baseline in both intention to treat and as treated analyses (fig 2⇓).
In our large, non-experimental cohort study, starting orlistat treatment was not associated with an increased risk of colorectal cancer among patients aged 18 years or over in the UK Clinical Practice Research Datalink (CPRD). These findings were consistent in sensitivity analyses and subgroup analyses. Orlistat initiators and matched non-initiators had similar baseline characteristics, with only slight difference in previous diagnosis of and treatment for diabetes and hypertension. Our findings provide evidence that use of orlistat does not alter the risk of colorectal cancer.
Although our estimates were based on a small number of events despite the size of the study population, the adjusted hazard ratio was 1.11 with a 95% confidence interval ranging from 0.84 to 1.47, showing not only acceptable precision of our estimate but also that our data are not compatible with a meaningful harmful effect of orlistat treatment on the risk of colorectal cancer. Our findings support the US Food and Drug Administration’s conclusion of no increased risk of colorectal cancer associated with the use of orlistat. The FDA’s report was based on the negative results from pooled clinical trials and a small number of cases of colon cancer from the spontaneous adverse event reporting system. Our study, based on a large, population based healthcare database, represents people actually taking orlistat in the real world, who tend to be different from the participants in clinical trials.
Recent studies showed that a reduction in body mass index could decrease the risk of colon cancer,16 17 18 so our results need to be considered in light of the potential protective effect of orlistat induced weight loss in obese people. Unfortunately, we do not have enough follow-up data on body mass index to estimate the magnitude of the effect of orlistat induced weight loss. Given the average orlistat induced weight loss and a short follow-up time in our study, we would not expect a relevant protective effect of orlistat induced weight loss on the incidence of colorectal cancer. Moreover, although this is of scientific interest, we would mainly be interested in the overall effect of orlistat on colorectal cancer incidence from an individual or public health perspective.
In the sensitivity analyses for induction and latency periods, the results were not substantially altered by the length of induction and latency periods, and the absence of association between orlistat and colorectal cancer was consistent throughout all scenarios. Risk of colorectal cancer may change over time after orlistat initiation. We did not observe a monotonic trend of hazard ratios of colorectal cancer over time (fig 1⇑). Although higher risks of colorectal cancer were seen with follow-up of 24 months or longer, the estimates were hampered by wide confidence intervals owing to a small number of colorectal cancer events.
Limitations of study
Our study had several limitations. Non-adherence is of concern. To increase the chances that patients were truly exposed to orlistat, we required at least two continuous prescriptions. We were unable to use an active comparator cohort because the number of patients starting weight reduction drugs other than orlistat was too small. We recognize that the follow-up time is not long enough to observe an effect on initiation of colorectal cancer, so all we can say is that orlistat does not seem to have an effect on promotion of colorectal cancer. Thus, our analysis cannot exclude the possibility of an increased risk of colorectal cancer after long term use of orlistat. Nevertheless, in our data, the short follow-up time based on as treated analysis also indicates that most patients do not take orlistat continuously for a prolonged time.
As this was a non-experimental study, our results may be affected by unmeasured confounding. Fat distribution, usually measured as waist circumference, is a moderate risk factor for colorectal cancer, partially independent of body mass index, and might be positively correlated with the probability of taking orlistat.19 20 Unfortunately, the CPRD fails to capture information on fat distribution. Common side effects of orlistat are gastrointestinal, such as abdominal pain or oily stool, potentially leading to diagnostic endoscopies. This could lead to an earlier diagnosis of (asymptomatic) colorectal cancer, resulting in an increased hazard ratio, but cannot explain our finding; on the other hand, endoscopies also could lead to early removal of colonic adenomatous polyps, resulting in a reduced long term risk of colorectal cancer, but we would expect such a beneficial effect to take several years to become apparent. We also examined the frequency of patients who underwent screening for colorectal cancer within one year after cohort entry and found no difference between orlistat initiator and non-initiators cohorts (0.37% v 0.38%). The generalizability of the results is also limited by the lack of information on race/ethnicity in the CPRD.
Our study provides no evidence of an increased risk of colorectal cancer after starting orlistat treatment in UK adults. The study is limited by the relatively short follow-up time, and we cannot exclude the possibility of adverse effects of long term orlistat use on risk of colorectal cancer.
What is already known on this topic
Orlistat is one of the most widely used anti-obesity drugs and is the only over the counter drug for weight loss approved in the United States and Europe
An animal study showed that orlistat may induce aberrant crypt foci in rodents, but data from population based post-marketing studies on the risk of colorectal cancer are lacking
What this study adds
This study in the UK population showed no evidence of an increased risk of colorectal cancer associated with use of orlistat
The study is limited by the relatively short follow-up time, and the possibility of adverse effects of long term orlistat use on risk of colorectal cancer cannot be excluded
Cite this as: BMJ 2013;347:f5039
We thank Pascal Egger for help with data management.
Contributors: J-LH, TS, RSS, and CRM conceived and designed the study. TS oversaw the conduct of the study. CRM and SSJ provided the data and oversaw the database programming. J-LH did the data analysis. J-LH and TS interpreted the results and drafted the manuscript. TS, RSS, CRM, and SSJ contributed to critical revision of the manuscript for important intellectual content. All authors approved the final manuscript. TS is the guarantor.
Funding: The study was funded by the population research award from the Lineberger Comprehensive Cancer Center (LCCC) at the University of North Carolina at Chapel Hill and R01 AG023178 from the National Institute of Aging at the National Institutes of Health. The funding agencies had no role in the design of the study; in the analysis and interpretation of the data; in the writing of the report; or in the decision to submit the paper for publication.
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: JLH and TS receive(d) salary support from the Center for Pharmacoepidemiology, Department of Epidemiology, the University of North Carolina at Chapel Hill, currently funded by GlaxoSmithKline (a pharmaceutical company that produces Alli, the brand name of orlistat 60 mg); no other relationships or activities that could appear to have influenced the submitted work.
Ethical approval: This study was approved by the Independent Scientific Advisory Committee for MHRA database research in the UK and was exempt from the Institutional Review Board review at the University of North Carolina at Chapel Hill.
Data sharing: No additional data available.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.